Skip to main content

MW 293.72 Da, Purity >98%. Potent and selective COX-2 inhibitor (Ki = 60 nM). Orally active. Anti-inflammatory agent. Active in vivo and in vitro.

Be the first to review this product! Submit a review

Images

Chemical Structure - Lumiracoxib, COX-2 inhibitor (AB142908), expandable thumbnail

Key facts

CAS number
220991-20-8
Purity
> 98%
Form
Solid
Molecular weight
293.72 Da
Molecular formula
C15H13ClFNO2
PubChem identifier
151166
Nature
Synthetic

Target data

Alternative names

Cyclooxygenase, Cyclooxygenase 2b, Cyclooxygenase 3, included, Cyclooxygenase-1, Cyclooxygenase-2, EC 1.14.99.1, GRIPGHS, Glucocorticoid-regulated inflammatory Prostaglandin G/H synthase, Glucocorticoid-regulated inflammatory cyclooxygenase, Macrophage activation-associated marker protein P71/73, OTTHUMP00000033524, PCOX1, PES-2, PGG/HS, PGH synthase 1, PGH synthase 2, PGH1_HUMAN, PGH2_HUMAN, PGHS-1, PGHS-2, PHS 1, PHS 2, PHS II, PTGHS, PTGS1, PTGS2, Partial COX1 proteins, included, Prostaglandin G/H synthase, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 2 precursor, Prostaglandin G/H synthase and cyclooxygenase, Prostaglandin H2 synthase 1, Prostaglandin H2 synthase 2, Prostaglandin-endoperoxide synthase 1, Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase), Prostaglandin-endoperoxide synthase 2, TIS10, TIS10 protein, fj02a10, hCox 2, prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), ptgs2a, unp1239, wu:fj02a10

Recommended products

MW 293.72 Da, Purity >98%. Potent and selective COX-2 inhibitor (Ki = 60 nM). Orally active. Anti-inflammatory agent. Active in vivo and in vitro.

Key facts

Purity
> 98%
PubChem identifier
151166
Solubility

Soluble in DMSO to 100 mM.

Biochemical name
Lumiracoxib
Biological description

Potent and selective COX-2 inhibitor (Ki = 60 nM). Orally active. Anti-inflammatory agent. Active in vivo and in vitro.

Canonical SMILES
CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O
InChI
InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
InChIKey
KHPKQFYUPIUARC-UHFFFAOYSA-N
IUPAC name
2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid

Storage

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate long-term storage conditions
Ambient
Storage information
The product can be stored for up to 12 months

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Cyclooxygenase 2 (COX2) and Cyclooxygenase 1 (COX1) are enzymes that convert arachidonic acid into prostaglandins which are involved in inflammation and other physiological functions. COX2 also known as prostaglandin-endoperoxide synthase 2 has a molecular mass of approximately 72 kDa. COX1 sometimes called prostaglandin-endoperoxide synthase 1 has similar molecular weight. These enzymes are expressed in various tissues with COX1 found ubiquitously and COX2 expressed more selectively often induced by inflammatory stimuli.

Biological function summary

COX2 and COX1 help regulate processes like inflammation pain and fever through their role in prostaglandin synthesis. COX1 primarily maintains normal cellular processes while COX2 is highly inducible and becomes active during inflammatory responses. COX2 does not typically form complexes operating independently in the cellular environment to mediate inflammatory signals.

Pathways

COX2 and COX1 are key components in the prostaglandin biosynthetic pathway influencing pain and inflammatory pathways. Their activity affects the cyclooxygenase pathway important for converting arachidonic acid into prostaglandins and thromboxanes. COX enzymes interact closely with other proteins like prostaglandin synthases and thromboxane synthase which further modify their products into different prostaglandins and thromboxanes.

Associated diseases and disorders

COX2 links to conditions such as rheumatoid arthritis and colorectal cancer. Its increased expression often correlates with the inflammatory response seen in these illnesses. Inhibiting COX2 with drugs like lumiracoxib alleviates symptoms in inflammatory diseases. COX1 while less implicated in disease connects to interactions with other proteins indicating changes during digestive issues due to its role in gastric mucosa maintenance.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

1 product image

  • Chemical Structure - Lumiracoxib, COX-2 inhibitor (ab142908), expandable thumbnail

    Chemical Structure - Lumiracoxib, COX-2 inhibitor (ab142908)

    2D chemical structure image of ab142908, Lumiracoxib, COX-2 inhibitor

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com